SOURCE: Gene Express, Inc.

March 15, 2006 13:33 ET

Gene Express Co-Founder to Participate in Cambridge Healthtech Institute Quantitative PCR Meeting

TOLEDO, OH -- (MARKET WIRE) -- March 15, 2006 -- Gene Express, Inc. today announced that its co-founder and scientific and medical advisor, James C. Willey, MD, will participate as a scientific advisor at the Cambridge Healthtech Institute (CHI) Quantitative PCR meeting in San Diego on March 19-21.

Dr. Willey will speak on the "MAQC Discussion Panel" on Monday, March 20, 2006. The panel will report on the design and implementation of the MicroArray Quality Control (MAQC) project and highlight issues regarding standardization, data analysis, comparison of data across platforms, and comparison of quantitative PCR data to microarray data. In addition, Dr. Willey will host a focused group discussion entitled, "Use of Internal Standards or External Standard Curves in Quantitative PCR: Advantages and Disadvantages of Each."

Dr. Willey will also chair the morning session on March 21 entitled, "Applications -- Facilitating Diagnosis and Prognosis."

Gerald Vardzel, CEO of Gene Express, stated, "We are honored to have the counsel and support of a recognized industry expert such as Dr. Willey. His prominent participation at this meeting is illustrative of his contributions to this field of research."

Dr. Willey is a George Isaac Professor for Cancer Research and a professor of Medicine in Pulmonary and Critical Care Medicine at the Medical University of Ohio. He is also a member of the National Cancer Institute's Director's Challenge Program. Dr. Willey's area of specialty is lung cancer.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439
    E: Email Contact